News | Implantable Cardiac Monitor (ICM) | December 22, 2020

FDA Clears Fever-Detecting Cardiac Monitor From Biotronik

With the FDA clearance of the Vital Data Sensor, Biotronik's Biomonitor IIIm features two-in-one detection, providing physicians the ability to monitor for early signs of potential life-threatening cardiac arrhythmias and body temperature increases potentially associated with fever.

With the FDA clearance of the Vital Data Sensor, Biotronik's Biomonitor IIIm features two-in-one detection, providing physicians the ability to monitor for early signs of potential life-threatening cardiac arrhythmias and body temperature increases potentially associated with fever.

December 22, 2020 — The U.S. Food and Drug Administration (FDA) cleared Biotronik's Vital Data Sensor, which identifies body temperature increases potentially associated with fever, in the new Biomonitor IIIm injectable cardiac monitor (ICM). 

The fever monitoring technology was recently discussed in an article in the journal Heart Rhythm Case Reports.[1]

Physicians will now have access to daily reports on vital data, including body temperature, and cardiac arrhythmia data to help them monitor patient health and their treatment remotely. Biomonitor IIIm contains integrated sensor technologies designed to measure patient activity, heart rate and body temperature. The interrelationship between these vital signs and health conditions is well-documented, particularly fever, which leads to increases in mean and resting heart rates and possible decreases in activity levels.[2]

The first U.S. case using Biomonitor IIIm was performed by Luigi Di Biase, M.D., Ph.D. "The patient is at high risk for infection during this global pandemic due to underlying conditions. It is comforting for me and my patients knowing that we will be able to monitor for early signs of potential life-threatening cardiac arrhythmias and infections for up to 5.5 years. Coupled with the workflow advantages, this device is a step forward for injectable cardiac monitors," said Di Biase, who is the section head of electrophysiology and director of arrhythmia services at Montefiore Health System in New York City.

This exclusive integrated sensor in Biomonitor IIIm enables physicians to stay connected with cardiac patients and proactively monitor them for warning signs at home — preserving capacity in hospitals for the sickest patients. This meaningful digital health innovation can potentially provide earlier detection while helping to streamline remote patient management.

"Vital data trends help support the diagnosis for a range of illnesses and, given the additional impact of the current pandemic on cardiac health, we have worked with urgency to advance Biomonitor IIIm's unique sensor technology," said Dr. David Hayes, chief medical officer of Biotronik Inc. "Patients with cardiac conditions are at an increased risk for worse outcomes from many systemic illnesses, so closer monitoring of these patients may help manage potential symptoms associated with a febrile response, particularly if it can be done safely and remotely."

In addition to these benefits, Biomonitor IIIm is the industry leader in battery longevity with 5.5 years of continuous monitoring, providing long-term monitoring of chronic cardiac conditions.  Biomonitor devices have a unique design which facilitates a one-step injection procedure, delivers class-leading detection performance, and signal fidelity comparable to gold-standard 12-lead ECG recordings. In addition, the proven performance of Biotronik Home Monitoring ensures 98 percent daily transmission success for streamlined clinical device management.[3]

Related Implantable Monitor Content:

Next Generation Medtronic ICM Offers Remote Programming and Improved Longevity

VIDEO: Rising Interest in Remote Monitoring of EP Devices in the COVID-19 Era — Interview with Robert Kowal, M.D.

FDA Clears Boston Scientific LUX-Dx Insertable Cardiac Monitor

Biotronik Launches Biomonitor III Injectable Cardiac Monitor in Europe

Abbott Launches Next-generation Confirm RX Implantable Cardiac Monitor

Real-time vs. Post-monitoring Review Approaches to Holter, Event Recording

 

References:

1. Whittington RH et al. Temperature monitoring with an implantable loop recorder in a patient with presumed COVID-19. Heart Rhythm Case Reports. 2020, 6(8). https://www.heartrhythmcasereports.com/article/S2214-0271(20)30113-5/pdf

2. Jensen MM, Brabrand M. The relationship between body temperature, heart rate and respiratory rate in acute patients at admission to a medical care unit. Scand J Trauma Resusc Emerg Med 23, A12 (2015). https://doi.org/10.1186/1757-7241-23-S1-A12.

3. Mariani JA, et al. Miniaturized implantable cardiac monitor with a long sensing vector (BIOMONITOR III): Insertion procedure assessment, sensing performance, and home monitoring transmission success. J Electrocardiol. 2020;60:118–25. doi: 10.1016/j.jelectrocard.2020.04.004.

Related Content

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

News | Cardiac Diagnostics | January 06, 2021
January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects
The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en
heart disease image
News | Cardiac Diagnostics | December 18, 2019
December 18, 2019 — In their latest report, “...
FDA Warns Troponin Tests Impacted by Biotin Dietary Supplement
Feature | Cardiac Diagnostics | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — The U.S.
Videos | Cardiac Diagnostics | October 29, 2019
Doctor Clyde Yancy was a keynote speaker and said doctors need to check their assumptions about patients at the door...
79-year-old Tony Marovic had a right carotid endarterectomy shortly after discovering a 95 percent blockage of his carotid artery at a health and wellness screening event

79-year-old Tony Marovic had a right carotid endarterectomy shortly after discovering a 95 percent blockage of his carotid artery at a health and wellness screening event. Image courtesy of University Hospitals.

News | Cardiac Diagnostics | October 16, 2019
Health and wellness screenings are more than just nice events for the community – they can save lives. A Mentor, Ohio,...
Pesticide Exposure May Increase Heart Disease and Stroke Risk

Image courtesy of zefe wu from Pixabay

News | Cardiac Diagnostics | October 15, 2019
On-the-job exposure to high levels of pesticides raised the risk of heart disease and stroke in a generally healthy...